Physician and patient preferences for oral anticoagulation therapy decision making in atrial fibrillation: results from a national best–worst scaling survey in Türkiye

Basit Öğe Kaydı
dc.contributor.authorKılıçkesmez, Kadriye
dc.contributor.authorAras, Dursun
dc.contributor.authorDeğertekin, Muzaffer
dc.contributor.authorÖzer, Necla
dc.contributor.authorHacıbedel, Başak
dc.contributor.authorHelvacıoğlu, Kerem
dc.contributor.authorErgene, Oklay
dc.date.accessioned2025-12-05T10:49:28Z
dc.date.available2025-12-05T10:49:28Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractAtrial fibrillation (AF) is the most common cardiac dysrhythmia and a common cause of ischemic stroke. Stroke prevention with oral anticoagulation (OAC) is the cornerstone of AF management. Patients and their treating physicians may have different views on different attributes of OACs. The objective of this study was to quantify the relative importance that patients and physicians in Turkey place on different OAC attributes when making treatment decisions in AF. A cross-sectional survey was administered to AF patients (≥ 50 years) receiving OAC and practising cardiologists, including residents with ≥ 2 years of experience in Turkey. For both patients (N = 230; 50% male) and physicians (N = 194; 74% male), the most important attributes for OAC treatment decision making in AF were “success in preventing stroke” (57% and 73.9% or overall importance, respectively) and “risk of major bleeding” (20% and 23.4%, respectively). For patients, other attributes were much less important, but not altogether unimportant: reversal agent availability (7%), monitoring (5%), food or drug interactions (3%), minor bleeding (3%), and ease of swallowing (2%). For physicians, among the other attributes, only the need for monitoring (1.3%) had a relative importance of > 1%. For all Turkish participants, efficacy and safety were found to be the most important attributes influencing OAC choice in AF with these two attributes accounting for 77% and 97.3% of overall importance for patients and physicians, respectively. Certain considerations, especially reversal agent availability and monitoring appear to be more important to patients than to physicians This is the first study to use BWS to quantify patient and physician preferences for OAC treatments in AF in Turkey.
dc.description.sponsorshipPfizer
dc.identifier.citationKılıçkesmez, K., Aras, D., Değertekin, M., Özer, N., Hacıbedel, B., Helvacıoğlu, K. ... Ergene, O. (2024). Physician and patient preferences for oral anticoagulation therapy decision making in atrial fibrillation: results from a national best–worst scaling survey in Türkiye. Clinical Cardiology, 47(12). http://dx.doi.org/10.1002/clc.70038
dc.identifier.doi10.1002/clc.70038
dc.identifier.issn0160-9289
dc.identifier.issn1932-8737
dc.identifier.issue12
dc.identifier.pmid39654285
dc.identifier.scopus2-s2.0-85211196550
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1002/clc.70038
dc.identifier.urihttps://hdl.handle.net/20.500.12511/13286
dc.identifier.volume47
dc.identifier.wosWOS:001373537300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAras, Dursun
dc.language.isoen
dc.relation.ispartofClinical Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAtrial Fibrilation
dc.subjectNoacs
dc.subjectOral Anticoagulation
dc.subjectPatients' Preferences
dc.subjectTreatment Decision
dc.titlePhysician and patient preferences for oral anticoagulation therapy decision making in atrial fibrillation: results from a national best–worst scaling survey in Türkiye
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Aras-Dursun-2024.pdf
Boyut:
708.17 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu